应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01877 君实生物
交易中 07-03 13:57:59
11.720
+0.240
+2.09%
最高
11.880
最低
11.580
成交量
31.36万
今开
11.720
昨收
11.480
日振幅
2.61%
总市值
115.52亿
流通市值
25.70亿
总股本
9.86亿
成交额
368.28万
换手率
0.14%
流通股本
2.19亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
君实生物(01877):6月累计回购3.44万股A股
智通财经 · 07-02 19:03
君实生物(01877):6月累计回购3.44万股A股
君实生物:累计回购约82万股
每日经济新闻 · 07-02 18:14
君实生物:累计回购约82万股
南向资金6月28日净卖出君实生物51.76万股 连续3日减持
自选股智能写手 · 07-02 09:31
南向资金6月28日净卖出君实生物51.76万股 连续3日减持
7月1日君实生物现513万元大宗交易
证券之星 · 07-01 17:20
7月1日君实生物现513万元大宗交易
君实生物6月27日现1笔大宗交易 成交金额590万元
智能小浪 · 06-27
君实生物6月27日现1笔大宗交易 成交金额590万元
6月27日君实生物现590万元大宗交易
证券之星 · 06-27
6月27日君实生物现590万元大宗交易
君实生物06月26日主力资金流入3万元 连续3日加仓
自选股智能写手 · 06-26
君实生物06月26日主力资金流入3万元 连续3日加仓
君实生物现涨近4% 特瑞普利单抗三阴性乳腺癌适应症在中国获批
新浪港股 · 06-26
君实生物现涨近4% 特瑞普利单抗三阴性乳腺癌适应症在中国获批
君实生物(01877)上涨5.23%,报11.66元/股
金融界 · 06-26
君实生物(01877)上涨5.23%,报11.66元/股
君实生物盘中异动 早盘股价大涨5.23%报11.661港元
自选股智能写手 · 06-26
君实生物盘中异动 早盘股价大涨5.23%报11.661港元
高质量创新成为国产药品开发主旋律,港股创新药ETF(159567)跟踪指数走势占优,中国生物制药、君实生物、来凯医药-B领涨。
有连云 · 06-26
高质量创新成为国产药品开发主旋律,港股创新药ETF(159567)跟踪指数走势占优,中国生物制药、君实生物、来凯医药-B领涨。
港股异动 | 君实生物(01877)涨超3% 特瑞普利单抗三阴性乳腺癌适应症在中国获批
智通财经 · 06-26
港股异动 | 君实生物(01877)涨超3% 特瑞普利单抗三阴性乳腺癌适应症在中国获批
君实生物获融资买入0.31亿元,近三日累计买入0.46亿元
金融界 · 06-26
君实生物获融资买入0.31亿元,近三日累计买入0.46亿元
君实生物(01877):特瑞普利单抗用于晚期三阴性乳腺癌一线治疗的新适应症上市申请获批准
智通财经 · 06-25
君实生物(01877):特瑞普利单抗用于晚期三阴性乳腺癌一线治疗的新适应症上市申请获批准
君实生物(688180.SH):特瑞普利单抗用于晚期三阴性乳腺癌一线治疗的新适应症上市申请获批
智通财经 · 06-25
君实生物(688180.SH):特瑞普利单抗用于晚期三阴性乳腺癌一线治疗的新适应症上市申请获批
君实生物:特瑞普利单抗新适应症上市申请获批
每日经济新闻 · 06-25
君实生物:特瑞普利单抗新适应症上市申请获批
智通AH统计|6月24日
智通财经 · 06-24
智通AH统计|6月24日
君实生物:霍依莲女士当选为公司第四届监事会职工代表监事
金融界 · 06-21
君实生物:霍依莲女士当选为公司第四届监事会职工代表监事
君实生物(01877):熊俊获选为第四届董事会主席
智通财经 · 06-21
君实生物(01877):熊俊获选为第四届董事会主席
加载更多
公司概况
公司名称:
君实生物
所属市场:
SEHK
上市日期:
--
主营业务:
上海君实生物医药科技股份有限公司是一家主要从事创新驱动型生物制药业务的中国公司。该公司主要开发创新药物,并全球范围内提供临床研究商业化服务。该公司产品覆盖肿瘤免疫治疗、代谢类疾病、炎症或自身免疫性疾病及神经系统疾病等多个治疗领域。该公司的药品主要用于治疗黑色素瘤、鼻咽癌、食管癌、尿路上皮癌、恶性淋巴瘤等。该公司主要于国内及海外市场提供产品。
发行价格:
--
{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":11.72,"timestamp":1719986149272,"preClose":11.48,"halted":0,"volume":313600,"delay":0,"floatShares":219295700,"shares":985689871,"eps":-2.47966,"marketStatus":"交易中","marketStatusCode":2,"change":0.24,"latestTime":"07-03 13:57:59","open":11.72,"high":11.88,"low":11.58,"amount":3682756,"amplitude":0.026132,"askPrice":11.78,"askSize":2800,"bidPrice":11.72,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.203649230834141,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1719994200000},"adr":0,"listingDate":1545580800000,"adjPreClose":11.48,"openAndCloseTimeList":[[1719970200000,1719979200000],[1719982800000,1719993600000]],"volumeRatio":0.670904,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":29.05,"timestamp":1719986271000,"preClose":28.71,"halted":0,"volume":2186229,"delay":0,"premium":"-62.25"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"2448134008","title":"君实生物(01877):6月累计回购3.44万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448134008","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448134008?lang=zh_cn&edition=full","pubTime":"2024-07-02 19:03","pubTimestamp":1719918181,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 发布公告,2024年6月,公司通过上海证券交易所交易系统以集中竞价交易方式已累计回购股份3.44万股,占公司总股本比例为0.0035%,回购成交的最高价为人民币29.14元/股,最低价为人民币29.03元/股,支付的资金总额为人民币99.998万元。本次回购股份进展符合法律法规的规定及公司回购股份方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144547.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","399300","BK1583","BK1161","BK1515","688180","159982","BK0239"],"gpt_icon":0},{"id":"2448136008","title":"君实生物:累计回购约82万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448136008","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448136008?lang=zh_cn&edition=full","pubTime":"2024-07-02 18:14","pubTimestamp":1719915263,"startTime":"0","endTime":"0","summary":"每经AI快讯,君实生物 7月2日晚间发布公告称,截至2024年6月30日,公司通过上海证券交易所交易系统以集中竞价交易方式已累计回购股份约82万股,占公司总股本比例为0.0828%,回购成交的最高价为人民币41.69元/股,最低价为人民币29.03元/股,支付的资金总额为人民币约3088万元。2023年1至12月份,君实生物的营业收入构成为:医药制造业占比98.11%。截至发稿,君实生物市值为283亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021814439565cb37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021814439565cb37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","BK1583","01877"],"gpt_icon":0},{"id":"2448297602","title":"南向资金6月28日净卖出君实生物51.76万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2448297602","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448297602?lang=zh_cn&edition=full","pubTime":"2024-07-02 09:31","pubTimestamp":1719883893,"startTime":"0","endTime":"0","summary":"6月28日,南向资金减持君实生物51.76万股连续3日减持。截止当日收盘,港股通共持有君实生物9148.36万股,占流通股41.70%。君实生物近5个交易日上涨3.72%,港股通累计减持26.22万股;近20个交易日上涨1.92%,港股通累计增持137.96万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407020941169ef0d58f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407020941169ef0d58f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688180","01877","BK0239"],"gpt_icon":0},{"id":"2448961142","title":"7月1日君实生物现513万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2448961142","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448961142?lang=zh_cn&edition=full","pubTime":"2024-07-01 17:20","pubTimestamp":1719825631,"startTime":"0","endTime":"0","summary":"近三个月该股共发生2笔大宗交易,合计成交3800.0手,折价成交1笔,溢价成交1笔。该股在过去半年内已有共计171.15万股限售解禁股上市,占公司总股本的0.17%。截至2024年7月1日收盘,君实生物报收于28.61元,下跌1.51%,换手率0.46%,成交量3.5万手,成交额9916.5万元。该股最近90天内共有8家机构给出评级,买入评级8家;过去90天内机构目标均价为56.15。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070100022668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","BK1583","BK1515","01877","688180"],"gpt_icon":0},{"id":"2446049589","title":"君实生物6月27日现1笔大宗交易 成交金额590万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446049589","media":"智能小浪","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446049589?lang=zh_cn&edition=full","pubTime":"2024-06-27 17:40","pubTimestamp":1719481200,"startTime":"0","endTime":"0","summary":" 6月27日,君实生物收涨0.07%,收盘价为29.21元,发生1笔大宗交易,合计成交量20万股,成交金额590万元。 进一步统计,近3个月内该股累计发生1笔大宗交易,合计成交金额为590万元。该股近5个交易日累计上涨1.85%,主力资金合计净流入100.26万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-06-27/doc-incaemyf5311050.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-06-27/doc-incaemyf5311050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","688180","BK0239","01877","BK1583","BK1161"],"gpt_icon":0},{"id":"2446586225","title":"6月27日君实生物现590万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2446586225","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446586225?lang=zh_cn&edition=full","pubTime":"2024-06-27 17:20","pubTimestamp":1719480029,"startTime":"0","endTime":"0","summary":"近三个月该股共发生1笔大宗交易,合计成交2000.0手,溢价成交1笔。该股在过去半年内已有共计2.61亿股限售解禁股上市,占公司总股本的26.45%。截至2024年6月27日收盘,君实生物报收于29.21元,上涨0.07%,换手率0.67%,成交量5.15万手,成交额1.51亿元。该股最近90天内共有8家机构给出评级,买入评级8家;过去90天内机构目标均价为56.15。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700033418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1583","BK1161","688180","BK0239","01877"],"gpt_icon":0},{"id":"2446355489","title":"君实生物06月26日主力资金流入3万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2446355489","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446355489?lang=zh_cn&edition=full","pubTime":"2024-06-26 16:15","pubTimestamp":1719389711,"startTime":"0","endTime":"0","summary":"06月26日, 君实生物股价涨8.30%,报收12.00元,成交金额1764万元,换手率0.69%,振幅9.93%,量比2.53。君实生物今日主力资金净流入3万元,连续3日净流入,上一交易日主力净流入54万元,今日环比减少94.44%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为75.00%,平均涨幅为1.84%。该股近5个交易日上涨1.18%,主力资金累计净流入99万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流入274万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261615249f670874&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261615249f670874&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","01877","BK1161","BK1515"],"gpt_icon":0},{"id":"2446382344","title":"君实生物现涨近4% 特瑞普利单抗三阴性乳腺癌适应症在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2446382344","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446382344?lang=zh_cn&edition=full","pubTime":"2024-06-26 11:43","pubTimestamp":1719373395,"startTime":"0","endTime":"0","summary":"君实生物(01877)早盘上涨3.79%,现报11.50港元,成交额688.82万港元。\n 君实生物宣布,由公司自主研发的抗PD-1单抗药物特瑞普利单抗(商品名:拓益)联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得国家药监局(NMPA)批准。这是特瑞普利单抗在内地获批的第十项适应症。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-26/doc-inazzscp6289173.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-26/doc-inazzscp6289173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1583","01877","BK1161","BK1515"],"gpt_icon":0},{"id":"2446846343","title":"君实生物(01877)上涨5.23%,报11.66元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446846343","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446846343?lang=zh_cn&edition=full","pubTime":"2024-06-26 11:24","pubTimestamp":1719372254,"startTime":"0","endTime":"0","summary":"6月26日,君实生物(01877)盘中上涨5.23%,截至11:24,报11.66元/股,成交623.15万元。上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法,特别是在肿瘤免疫疗法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。截至2024年一季报,君实生物营业总收入3.81亿元、净利润-2.83亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/26112441197821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01877","688180","BK1583","BK1161","BK1515","BK0239"],"gpt_icon":0},{"id":"2446757384","title":"君实生物盘中异动 早盘股价大涨5.23%报11.661港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446757384","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446757384?lang=zh_cn&edition=full","pubTime":"2024-06-26 11:24","pubTimestamp":1719372249,"startTime":"0","endTime":"0","summary":"2024年06月26日早盘11时24分,君实生物股票出现异动,股价快速拉升5.23%。截至发稿,该股报11.661港元/股,成交量50.44万股,换手率0.23%,振幅5.05%。资金方面,该股资金流入316.648万港元,流出164.413万港元。君实生物股票所在的生物技术行业中,整体跌幅为0.63%。截至本公告日期,特瑞普利单抗的10项适应症已于中国内地获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240626112410af8f3828&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240626112410af8f3828&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","01877","688180"],"gpt_icon":0},{"id":"2446438694","title":"高质量创新成为国产药品开发主旋律,港股创新药ETF(159567)跟踪指数走势占优,中国生物制药、君实生物、来凯医药-B领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446438694","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446438694?lang=zh_cn&edition=full","pubTime":"2024-06-26 10:41","pubTimestamp":1719369706,"startTime":"0","endTime":"0","summary":"2024年6月26日,港股创新药板块领跑港股市场。盘面上,中国生物制药领涨,君实生物、来凯医药-B跟涨,港股创新药ETF市场热度较高,过去5个交易日日均成交额高达5977万元。国联证券表示,高质量创新成为国产药品开发主旋律。进入2024年,创新药首发定价征求意见稿和各地创新药全产业链支持政策文件的出台充分体现了国家对高质量创新药研发的鼓励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261041509f660336&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261041509f660336&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1191","01877","688180","BK1161","BK1589","BK1521","BK1583","02105","BK1515"],"gpt_icon":0},{"id":"2446381270","title":"港股异动 | 君实生物(01877)涨超3% 特瑞普利单抗三阴性乳腺癌适应症在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2446381270","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446381270?lang=zh_cn&edition=full","pubTime":"2024-06-26 10:39","pubTimestamp":1719369574,"startTime":"0","endTime":"0","summary":"消息面上,君实生物宣布,由公司自主研发的抗PD-1单抗药物特瑞普利单抗联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得国家药监局批准。这是特瑞普利单抗在内地获批的第十项适应症。天风证券此前指出,公司营业收入增长主要来自商业化药品销售收入的增长,其中核心产品特瑞普利单抗贡献突出。2023 年,特瑞普利单抗销售收入9.19 亿元,同比增长约24.93%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0239","BK1583","BK1515","01877","688180","YANG","07226","HSCEI","HSTECH"],"gpt_icon":0},{"id":"2446804395","title":"君实生物获融资买入0.31亿元,近三日累计买入0.46亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446804395","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446804395?lang=zh_cn&edition=full","pubTime":"2024-06-26 08:21","pubTimestamp":1719361305,"startTime":"0","endTime":"0","summary":"6月25日,沪深两融数据显示,君实生物获融资买入额0.31亿元,居两市第166位,当日融资偿还额0.12亿元,净买入1907.66万元。最近三个交易日,21日-25日,君实生物分别获融资买入0.09亿元、0.07亿元、0.31亿元。融券方面,当日融券卖出2.24万股,净买入15.60万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406260821579f6599c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406260821579f6599c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1583","BK1161","BK1515","688180"],"gpt_icon":0},{"id":"2446843481","title":"君实生物(01877):特瑞普利单抗用于晚期三阴性乳腺癌一线治疗的新适应症上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2446843481","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446843481?lang=zh_cn&edition=full","pubTime":"2024-06-25 20:54","pubTimestamp":1719320064,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 发布公告,公司收到国家药品监督管理局核准签发的《药品注册证书》,公司产品特瑞普利单抗联合注射用紫杉醇用于经充分验证的检测评估PD-L1 阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得批准。截至本公告日期,特瑞普利单抗的10项适应症已于中国内地获批。在国际化布局方面,2023年10月,特瑞普利单抗已作为首款鼻咽癌药物在美国获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688180","BK0239","BK1583","01877","BK1515","BK1161"],"gpt_icon":0},{"id":"2446817835","title":"君实生物(688180.SH):特瑞普利单抗用于晚期三阴性乳腺癌一线治疗的新适应症上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2446817835","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446817835?lang=zh_cn&edition=full","pubTime":"2024-06-25 19:56","pubTimestamp":1719316611,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 公告,近日,公司收到国家药品监督管理局核准签发的《药品注册证书》,特瑞普利单抗联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得批准,这是特瑞普利单抗在中国内地获批的第十项适应症。中国目前的晚期三阴性乳腺癌治疗仍以化疗为主,但无论单药或是联合化疗均疗效欠佳,中位生存期约为9至12个月,5年生存率不足30%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0239","01877","BK1515","688180","BK1583"],"gpt_icon":0},{"id":"2446814553","title":"君实生物:特瑞普利单抗新适应症上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2446814553","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446814553?lang=zh_cn&edition=full","pubTime":"2024-06-25 19:20","pubTimestamp":1719314428,"startTime":"0","endTime":"0","summary":"君实生物公告,特瑞普利单抗(商品名:拓益?,产品代号:JS001)联合注射用紫杉醇(白蛋白结合型)用于经充分验证的检测评估PD-L1阳性(CPS≥1)的复发或转移性三阴性乳腺癌(TNBC)的一线治疗的新适应症上市申请获得批准,这是特瑞普利单抗在中国内地获批的第十项适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202406253113278784.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202406253113278784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","01877","BK1583","BK1515"],"gpt_icon":0},{"id":"2445604282","title":"智通AH统计|6月24日","url":"https://stock-news.laohu8.com/highlight/detail?id=2445604282","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445604282?lang=zh_cn&edition=full","pubTime":"2024-06-24 16:15","pubTimestamp":1719216905,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示,截止6月24日收盘,东北电气、弘业期货、浙江世宝分列AH溢价率前三位,溢价率分别为1250.00%、599.19%、557.29%;招商银行、紫金矿业、福耀玻璃分列AH溢价率末三位,溢价率分别为15.28%、24.88%、25.29%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01057","02899","03908","02218","06690","LU1226287529.USD","01375","81211","02009","L","06826","01088","03143","01658","03606","06185","01211","06066","BYDDY","02866","002594","00753","01772","00042","01877","02338","159982","SG9999002828.SGD","01776","00317","601318","399300","02318","00553","00895","03968","82318","06178","01330","01919","03145","00187","06837","00588","01033","06865","01349","06869","03678"],"gpt_icon":0},{"id":"2445309764","title":"君实生物:霍依莲女士当选为公司第四届监事会职工代表监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2445309764","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445309764?lang=zh_cn&edition=full","pubTime":"2024-06-21 23:31","pubTimestamp":1718983889,"startTime":"0","endTime":"0","summary":"6月21日消息, 君实生物 公告称,第三届监事会任期届满,根据相关规定,公司于 2024 年 6 月 20 日召开职工代表大会,选举霍依莲女士为公司第四届监事会职工代表监事,任期与公司第四届监事会任期一致。霍依莲女士将与公司股东大会选举产生的 2 名非职工代表监事共同组成公司第四届监事会。截至本公告披露日,霍依莲女士未直接持有公司股份,并且在公司法等相关法律、法规和规定要求的任职条件上都符合要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406212339419f56ff5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406212339419f56ff5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1583","BK1515","688180","BK1161"],"gpt_icon":0},{"id":"2445765446","title":"君实生物(01877):熊俊获选为第四届董事会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2445765446","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445765446?lang=zh_cn&edition=full","pubTime":"2024-06-21 22:28","pubTimestamp":1718980085,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 发布公告,全部建议董事已于股东周年大会上获选,并构成第四届董事会。于2024年6月21日举行的第四届董事会第一次会议上,熊俊及李宁分别获选为第四届董事会主席及副主席,任期为三年,自董事会会议日期起生效,直至第四届董事会结束。于2024年6月20日举行的公司职工代表会议上,职工代表决议委任霍依莲为第四届监事会的职工代表监事。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688180","BK1583","BK1515","01877","BK1161"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0361},{"period":"1month","weight":-0.0697},{"period":"3month","weight":0.1526},{"period":"6month","weight":-0.3958},{"period":"1year","weight":-0.5073},{"period":"ytd","weight":-0.4095}],"compareEarnings":[{"period":"1week","weight":-0.0168},{"period":"1month","weight":-0.0172},{"period":"3month","weight":0.0624},{"period":"6month","weight":0.0675},{"period":"1year","weight":-0.0796},{"period":"ytd","weight":0.0423}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动型生物制药业务的中国公司。该公司主要开发创新药物,并全球范围内提供临床研究商业化服务。该公司产品覆盖肿瘤免疫治疗、代谢类疾病、炎症或自身免疫性疾病及神经系统疾病等多个治疗领域。该公司的药品主要用于治疗黑色素瘤、鼻咽癌、食管癌、尿路上皮癌、恶性淋巴瘤等。该公司主要于国内及海外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.122873},{"month":2,"riseRate":0.833333,"avgChangeRate":0.02917},{"month":3,"riseRate":0.666667,"avgChangeRate":0.049114},{"month":4,"riseRate":0.833333,"avgChangeRate":0.112597},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.034116},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.02585},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.066568},{"month":8,"riseRate":0,"avgChangeRate":-0.093613},{"month":9,"riseRate":0,"avgChangeRate":-0.097134},{"month":10,"riseRate":0.4,"avgChangeRate":0.053036},{"month":11,"riseRate":0.6,"avgChangeRate":0.067975},{"month":12,"riseRate":0.8,"avgChangeRate":0.175695}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}